Numerous Fossils Reveal Jurassic Fish Killed in Same, Bizarre Way
A new analysis of fossilized Tharsis fish reveals that the carnivorous marine animals seem to have frequently met their end with large cephalopods known as belemnites lodged quite fatally in their gullets.
According to paleontologists Martin Ebert and Martina Kölbl-Ebert of Ludwig Maximilian University of Munich in Germany, Tharsis fish found in the 152 million-year-old Solnhofen Plattenkalk (limestone) formation in Germany appear in multiple instances to have died while attempting to swallow a belemnite nearly as long as themselves.
"A recent review of collection material … uncovered several specimens of Tharsis from the Late Jurassic Plattenkalk deposits of the Solnhofen Archipelago with belemnites wedged in mouth and gill apparatus," they write in their paper.
"In all cases, the rostrum [beak] reexits through the gill apparatus, whereas the broad phragmocone [internal shell] of the belemnite is firmly lodged in the mouth opening."
Related: Ancient Tyrannosaur's Last Victims Can Still Be Seen Inside Its Stomach
Tharsis fish were what are known as micro-carnivores; animals that eat very small animals such as larvae and zooplankton, in this case by using suction to gulp down their food. Their fossils are quite common.
Belemnites, which resembled squid with a long hooded body and multiple arms, lived in the open ocean, left far fewer fossils.
Interestingly, the belemnite fossils found in the Plattenkalk basins of Eichstätt and Solnhofen often consist of an internal shell overgrown with bivalves – suggesting that the belemnite was dead, kept buoyant in the water column by a gas-filled shell colonized by other animals, such as clam-like molluscs, feasting on the decaying soft tissue.
Tharsis fish were unlikely to be looking for food amid the hostile conditions of the seafloor, nor would the fish have been preying directly on the belemnites – but the researchers believe they know why the dead, drifting cephalopods may have posed such a choking hazard for the hapless fish.
"Apparently, these micro-carnivore fish were in the habit of sucking remnants of decaying soft tissue or overgrowth such as algae or bacterial growth from floating objects, but when a streamlined floating belemnite rostrum accidentally was sucked into the mouth, they were no longer able to get rid of these deadly objects," the paleontologists write in their paper.
"Even though the fish tried to pass the obstructive item through its gills, there was no way of getting rid of it, leading to death by suffocation."
Sounds deeply unpleasant, really.
The research has been published in Scientific Reports.
'Ball Lightning' Caught on Film After Storm in Canada
Expired Cans of Salmon From Decades Ago Contained a Huge Surprise
Melting Glaciers Could Reawaken Hundreds of Earth's Volcanoes
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Topflight Pharma Development Veteran Joins Synendos
Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy Dr. George Garibaldi, MD BASEL, Switzerland, July 15, 2025 (GLOBE NEWSWIRE) -- Synendos Therapeutics ('Synendos'), the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced today that it has named Dr. George Garibaldi, CMO. This appointment is particularly timely as the company moves towards Phase 2 clinical development of its lead drug asset SYT-510. Synendos CEO, Andrea Chicca said, "It's tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.' Dr. George Garibaldi is a psychiatrist and neuroscientist with more than 30 years of experience leading global clinical development programs in CNS disorders. His career spans leadership roles at Roche, Novartis and Janssen, where he oversaw the development of breakthrough treatments including Ocrevus® for primary progressive and relapsing remitting multiple sclerosis and Exelon® for Alzheimer's disease and Lewi body dementia. As co-founder of Noema Pharma, he spearheaded the in-licensing and advancement of shelved CNS assets, securing major venture funding and progressing them through pivotal clinical trials. Known for his strong beliefs in empowering patients, Dr. Garibaldi has published more than 100 peer-reviewed articles and has developed widely used clinician- and patient-reported outcome measures. He is a founder and past president of the International Society for CNS Clinical Trials and Methodology and is recognized by peers as a collaborative, strategic leader dedicated to advancing mental health and neuroscience therapeutics. 'Mental health and brain health have for far too long been underserved by traditional drug development models,' said Dr. Garibaldi. "Synendos is combining the pursuit of an innovative target with a commitment to rethinking how we design trials, measure outcomes and prioritize patient function. It's this willingness to be ahead of the curve with therapeutic innovation and a genuine patient focus that made me want to be part of the company.' He added, 'Society today recognizes that there is no health without mental health. We have the rare opportunity to chart our own path here. I am eager to lead this transformation and help this exceptional team advance the next generation of brain therapies that could truly change the lives of patients.' About SynendosSynendos is a clinical-stage, neuroscience company developing potentially breakthrough therapies for neuropsychiatric and other CNS disorders such as anxiety disorders, PTSD and other indications. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos' lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action (MoA) with the potential to deliver meaningful benefits to patients. This novel MoA has the potential to combine treatment of a range of symptoms with sustained efficacy in large patient populations together with the potential to address a key unmet need, that of chronic tolerability, allowing more patients to stay on treatment and regain an improved quality of life. For more information please contact: Synendos Therapeutics AG Simon Russell +41 79 138 5840 O Public Relations GmbHO'Patrick Wilson o@ 78 888 4332 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Welsh Ambulance Service to lead study on emergency video consultation
Live video consultations could be used to help decision-making in response to 999 calls following a study being led ay the Welsh Ambulance Service. The 999 RESPOND-2 study is being funded by the National Institute for Health and Care Research and aims to improve decision-making around whether to send Enhanced Critical Care Teams to emergency calls. These teams deliver advanced care for seriously ill and injured patients at the scene of an incident. It is currently difficult for control room clinicians to fully capture the complexity and volume of information they need to make the best decision. Advances in technology have enabled ambulance services to test live-stream video from callers' smart phones during an emergency call, to help ambulance staff assess quickly and accurately how urgently help is needed for an unwell patient. Professor Nigel Rees, assistant director of research and innovation at the Welsh Ambulance Service, said: 'We're studying how emergency critical care teams size up risk and severity in high pressured and time sensitive situations. 'We are doing this by comparing video consultation calls, where clinicians can see the patient, the accident scene and other factors as opposed to traditional 999 calls, where the clinician can only make a decision based on descriptions from the caller. 'We hope to learn more about who sees what, who says what and how these decisions shape emergency response when seconds matter and really can be the difference between life and death. 'From major trauma to severe medical emergencies, ECCTs are integral to pre-hospital and emergency services, but they are a finite resource.' The study is the first to consider the impact of live-stream video in how people communicate with each other in 999 calls and to provide evidence on whether live-stream videos can overcome some limitations of audio 999 calls. It is a collaboration between clinicians and researchers across the Welsh Ambulance Service, West Midlands Ambulance Service, University of Warwick, University of Bristol, Imperial College London, Aberystwyth University, the Emergency Medical Retrieval and Transfer Service and the Wales Air Ambulance Charity.
Yahoo
7 hours ago
- Yahoo
Da Vinci's Vitruvian Man Encodes the Blueprint of Human Evolution, Says London Dentist
New research reveals a hidden geometric ratio in Leonardo's drawing that may define the endpoint of human evolution toward upright posturePhoto Courtesy of Rory Mac Sweeney LONDON, July 14, 2025 (GLOBE NEWSWIRE) -- A London-based dental surgeon and researcher, Dr. Rory Mac Sweeney of Precision Endodontics, has ignited international interest with a provocative reinterpretation of Leonardo da Vinci's Vitruvian Man. His newly published research suggests the Renaissance masterpiece encodes a precise geometric ratio that reflects the biomechanical endpoint of human evolution. Dr. Mac Sweeney's theory, published in the Journal of Mathematics and the Arts, identifies a hidden equilateral triangle embedded in Vitruvian Man. He connects this geometry to Bonwill's Triangle—a fundamental dental structure first described in the 19th century, which governs optimal jaw alignment and function. According to Mac Sweeney, this triangular structure appears throughout the body and is mathematically anchored by the ratio √8/3, or approximately 1.633. 'Leonardo's drawing isn't just a study in proportion—it's a map of tension,' said Dr. Mac Sweeney. 'The 1.633 ratio appears in the jaw, the spine, and the skull. It reflects a state known as vector equilibrium, where structural tension and compression are perfectly balanced. I believe this marks the final step in the human journey toward full upright posture.' This ratio, derived from the geometry of the cuboctahedron, is widely recognized in biomechanics and architecture as a hallmark of tensegrity—the balance of forces within a stable form. Dr. Mac Sweeney contends that this geometry defines the Vitruvian Morphotype: a form that nature has converged on through evolutionary pressures—not because it is aesthetically pleasing, but because it is structurally optimal. 'Human evolution has been a long progression toward uprightness,' he explained. 'The 1.633 ratio may represent our evolutionary omega point—a structural threshold beyond which no further anatomical adaptation is needed to stand, move, and balance efficiently in gravity.' Mac Sweeney suggests that fossil evidence should reveal a slow convergence toward this geometric configuration, particularly in the jaw. He highlights the emergence of Class I occlusion in the fossil record—also known as the overbite/overjet 'step'—around 8,000 years ago as a key moment. While small variations remain, he argues that modern Homo sapiens are the first species to fully express this morphotype. 'It's like the hydrodynamic form of a dolphin,' he said. 'Nature solves gravity the way it solves water. Vitruvian Man is the first full sketch of what that solution looks like.' Dr. Mac Sweeney's theory is now attracting attention from experts in evolutionary biology, bioengineering, and anatomical design. He is currently conducting interviews, public talks, and media appearances to discuss what he calls the Vitruvian Ratio—and its broader implications for anthropology, architecture, and even consciousness. 'Leonardo, somehow, saw it coming,' Mac Sweeney added. 'Vitruvian Man may be the only anatomical diagram ever created that captures not just what a human is—but what a human is becoming.' About Dr. Rory Mac Sweeney: Dr. Mac Sweeney is a London-based endodontist and researcher known for his interdisciplinary work in dental anatomy, geometry, and human evolution. His work explores the convergence of structural biology and classical design, and he is the author of the book The Paradox of Lucid Dreaming. @luciddreamyoga Contact Information: Contact person: Dr. Rory Mac SweeneyCompany name: Precision EndodonticsWebsite: [ Contact: rorymacsweeney@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data